Millstone Evans Group LLC Makes New $68,000 Investment in Zoetis Inc. (NYSE:ZTS)

Millstone Evans Group LLC bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 416 shares of the company’s stock, valued at approximately $68,000.

Other large investors also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC grew its stake in Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after buying an additional 140 shares in the last quarter. Rakuten Securities Inc. increased its stake in Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 166 shares during the last quarter. Dunhill Financial LLC raised its position in Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares in the last quarter. Asset Planning Inc bought a new stake in Zoetis during the fourth quarter worth $58,000. Finally, Quarry LP boosted its holdings in shares of Zoetis by 45.9% in the 3rd quarter. Quarry LP now owns 305 shares of the company’s stock valued at $60,000 after purchasing an additional 96 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is currently owned by company insiders.

Zoetis Price Performance

ZTS stock opened at $162.86 on Monday. The company has a market capitalization of $72.93 billion, a P/E ratio of 29.77, a PEG ratio of 2.78 and a beta of 0.94. The company has a fifty day moving average price of $166.76 and a 200-day moving average price of $175.38. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.33.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. As a group, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.23%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is presently 36.56%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on ZTS shares. Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus lowered their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, Piper Sandler raised their target price on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has an average rating of “Buy” and an average price target of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.